JAK3 covalent inhibitor-2
JAK3 covalent inhibitor-2 (compound J1b) is a selective, orally potent JAK3 inhibitor (IC50=7.2 nM) with low toxicity, anti-inflammatory activity and good bioavailability[1].
Product Specifications
CAS Number
[2664050-97-7]
UNSPSC
12352005
Target
Apoptosis; JAK
Type
Reference compound
Related Pathways
Apoptosis; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/jak3-covalent-inhibitor-2.html
Solubility
10 mM in DMSO
Smiles
[O-][N+](C1=CC=CC(C2=CNC3=NC=NC(N4C[C@H](NC(C=C)=O)CCC4)=C32)=C1)=O
Molecular Formula
C20H20N6O3
Molecular Weight
392.41
References & Citations
[1]Hualiang Y et al. Design and synthesis of highly selective Janus kinase 3 covalent inhibitors for the treatment of rheumatoid arthritis ARCH PHARM. 2024 Feb e2300753
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
JAK3
More Discoveries
Explore Other Products
Browse additional items from our catalog
363720 200 µL
IL6 (Interleukin 6, MGI2-A, MGI2A, HGF, BSF2, HSF, IFNB2, B-Cell Stimulatory Factor-2, Hybridoma/Plasmacytoma Growth Factor, Hepatocyte Stimulating Factor, Cytotoxic T-Cell Differentiation Factor)
Sign In for Pricing
View Details 
MBS1305451-01 0.5 mg (E-Coli)
Recombinant Rat Single Ig IL-1-related receptor (Sigirr), partial
Sign In for Pricing
View Details